Premium
Downregulation of nicotinamide nucleotide transhydrogenase and its naturally occurring antisense RNA in gastric cancer
Author(s) -
Esfandi Farbod,
Taheri Mohammad,
Kahaei Mir Salar,
Omrani Mir Davood,
Kholghi Oskooei Vahid,
GhafouriFard Soudeh
Publication year - 2019
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/ajco.13230
Subject(s) - downregulation and upregulation , nucleotide , antisense rna , cancer , chemistry , rna , microbiology and biotechnology , biochemistry , biology , gene , genetics
Abstract Aim Nicotinamide Nucleotide Transhydrogenase ( NNT ) gene encodes a protein, which is an important antioxidative enzyme that converts NADH to NADPH. This enzyme provides a significant proportion of the entire NADPH resource in the mitochondria. Previous reports have shown possible contribution of this gene in the carcinogenesis process. Methods In the current research, we evaluated expression levels of NNT gene and a naturally occurring antisense RNA ( NNT‐AS1 ) in gastric cancer specimens compared to their corresponding adjacent noncancerous tissues (ANCTs). Results Both NNT1 and NNT‐AS1 genes were significantly downregulated in tumor tissues compared to ANCTs (expression ratio = 0.369, p = .045 and expression ratio = 0.368, p = .043, respectively). Transcript levels of NNT1 and NNT‐AS1 were associated with the location of the primary tumor ( p = .003 and .002, respectively). Moreover, expressions of both genes were significantly elevated in tumors with lymphatic/vascular invasion compared to tumors without lymphatic/vascular invasion ( p = .001 and p = .005). No other remarkable associations were noticed between transcript levels of genes in tumor tissues and patients’ information. Based on the area under curve (AUC) values in the receiver operating characteristic (ROC) curves, the diagnostic power of NNT1 and NNT‐AS1 were estimated to be 0.62 and 0.63, respectively. Conclusions Although we demonstrated dysregulation of NNT1 and NNT‐AS1 in gastric tumor specimens in association with clinical data of patients, these two genes are not supposed to be appropriate biomarkers for gastric cancer.